Maravai LifeSciences Holdings Inc represents a strong commitment to innovation, excellence, and customer satisfaction. The company's corporate philosophy revolves around advancing global health solutions through cutting-edge technologies and scientific expertise. Maravai LifeSciences Holdings Inc values collaboration, integrity, and accountability, driving their mission to provide transformative products and services to the life sciences industry. With a focus on developing and delivering high-quality reagents, analytical instruments, and customized solutions, Maravai LifeSciences Holdings Inc strives to empower researchers, pharmaceutical companies, and diagnostic laboratories in their pursuit of breakthrough discoveries and medical advancements.

Maravai LifeSciences Holdings Inc is primarily present in the United States.

Maravai LifeSciences Holdings Inc has achieved several significant milestones. Firstly, the company successfully completed its initial public offering (IPO) on July 1, 2020, becoming a publicly traded company on the NASDAQ stock exchange under the ticker symbol MRVI. Additionally, Maravai has made notable acquisitions, such as the acquisition of MockV Solutions in June 2020, expanding its capabilities in viral vector manufacturing for gene and cell therapies. Moreover, Maravai has reported strong financial growth, with its revenue increasing 46% year-over-year in the second quarter of 2021. The company's dedication to innovation and strategic collaborations has positioned Maravai LifeSciences as a prominent player in the biotech industry.

Maravai LifeSciences Holdings Inc is a leading life sciences company specializing in providing critical products to enable the development of drug therapies, diagnostics, and vaccines. Founded in 2014, Maravai has rapidly established itself as a key player in the biopharmaceutical industry. The company focuses on four main business units, including nucleic acid production, biologics safety testing, protein detection, and in-vitro diagnostics. Maravai's history is characterized by continuous innovation, strategic partnerships, and a dedication to advancing global health through cutting-edge solutions. With its exceptional track record and unwavering commitment, Maravai LifeSciences Holdings Inc is poised to create a lasting impact in the life sciences field.

The main competitors of Maravai LifeSciences Holdings Inc in the market include companies such as Thermo Fisher Scientific, Agilent Technologies, and Illumina Inc. These companies also operate in the life sciences industry, offering a wide range of products and services, including laboratory instruments, reagents, and genomic solutions. However, Maravai LifeSciences Holdings Inc distinguishes itself through its expertise in the development of reagents and advanced technologies for the life sciences research community. With its innovative product portfolio and strong market presence, Maravai continues to compete effectively against its rivals in the industry.

Maravai LifeSciences Holdings Inc is primarily active in the biotechnology and life sciences industries.

Maravai LifeSciences Holdings Inc operates as a life sciences company that provides products and services to enable the development of drug therapies, diagnostics, and vaccines. The company's business model focuses on offering a comprehensive range of integrated solutions, including specialized reagents, consumables, software, and assay platforms. By leveraging its expertise in nucleic acid synthesis, bioprocess impurity testing, and protein labeling, Maravai supports the research and development efforts of pharmaceutical and biotechnology companies globally. As a trusted partner for life science applications, Maravai aims to accelerate scientific discoveries and improve patient outcomes through its innovative and customizable products and services.

Maravai LifeSciences Holdings KGV ir -139,81.

Maravai LifeSciences Holdings KUV ir 4,13.

AlleAktien kvalitātes vērtējums Maravai LifeSciences Holdings ir 1/10.

gaidāmā Maravai LifeSciences Holdings apgrozījums ir 281,11 milj. USD.

gaidāmā Maravai LifeSciences Holdings peļņa ir -8,31 milj. USD.

Maravai LifeSciences Holdings Inc. is a specialized biotechnology company focused on the development and manufacturing of products for large-scale biopharmaceutical production, in-vitro diagnostics, and research. The company focuses on developing innovative technologies and products that contribute to improving the health and well-being of humans and animals. It consists of three main areas: TriLink BioTechnologies, Vector Laboratories, and Cygnus Technologies, each specializing in developing products for the biopharmaceutical market. TriLink BioTechnologies manufactures reagents for nucleic acid synthesis and modification, as well as oligonucleotide-based genetics for body fluid analysis. Vector Laboratories is a leading provider of reagents for immunohistochemistry (IHC) and immunocytochemistry (ICC), including antibodies, kits, buffers, and reactivity cards. Cygnus Technologies is a leading manufacturer of products for the analysis of biopharmaceutical proteins, including ELISA kits, antibodies, protein markers, and reagents for protein purification. Maravai LifeSciences Holdings Inc. aims to develop innovative technologies and products that contribute to process improvement and cost savings. The company's products are designed to assist customers in the biopharmaceutical industry in focusing on drug development and therapy. Maravai also continuously invests in research and development to develop new technologies and products, always striving to offer customers the best and most innovative products. Overall, Maravai LifeSciences Holdings Inc. delivers innovative products that help customers in the biopharmaceutical industry optimize processes, maximize efficiency, and reduce costs. The company is committed to constantly evolving its products to provide customers with better solutions. Thanks to its ability to develop and deliver innovative products to its customers, Maravai LifeSciences Holdings Inc. remains a key player in the biopharmaceutical industry.

Maravai LifeSciences Holdings izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Maravai LifeSciences Holdings vai uzņēmums nedod dividendes.

Maravai LifeSciences Holdings ISIN ir US56600D1072.

Maravai LifeSciences Holdings WKN ir A2QHK8.

Maravai LifeSciences Holdings simbols ir MRVI.

Pēdējo 12 mēnešu laikā Maravai LifeSciences Holdings maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Maravai LifeSciences Holdings plāno maksāt dividendes 0 USD apmērā.

Maravai LifeSciences Holdings pašreizējā dividendu rentabilitāte ir .

Maravai LifeSciences Holdings maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Maravai LifeSciences Holdings pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Maravai LifeSciences Holdings tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Maravai LifeSciences Holdings apmērā 0 USD, kas tika izmaksāta 12.09.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 12.09.2024..

Pēdējās dividendes izmaksa notika 12.09.2024..

Gadā 2023, Maravai LifeSciences Holdings izmaksāja 0 USD dividendes.

Maravai LifeSciences Holdings dividendes tiek izmaksātas USD.